Stay Ahead of Compliance with Monthly Citation Updates


In your State Survey window and need a snapshot of your risks?

Survey Preparedness Report

One Time Fee
$79
  • Last 12 months of citation data in one tailored report
  • Pinpoint the tags driving penalties in facilities like yours
  • Jump to regulations and pathways used by surveyors
  • Access to your report within 2 hours of purchase
  • Easily share it with your team - no registration needed
Get Your Report Now →

Monthly citation updates straight to your inbox for ongoing preparation?

Monthly Citation Reports

$18.90 per month
  • Latest citation updates delivered monthly to your email
  • Citations organized by compliance areas
  • Shared automatically with your team, by area
  • Customizable for your state(s) of interest
  • Direct links to CMS documentation relevant parts
Learn more →

Save Hours of Work with AI-Powered Plan of Correction Writer


One-Time Fee

$49 per Plan of Correction
Volume discounts available – save up to 20%
  • Quickly search for approved POC from other facilities
  • Instant access
  • Intuitive interface
  • No recurring fees
  • Save hours of work
F0756
D

Failure to Document Physician Response to Pharmacy Recommendations

Bryn Mawr, Pennsylvania Survey Completed on 04-10-2025

Penalty

No penalty information released
tooltip icon
The penalty, as released by CMS, applies to the entire inspection this citation is part of, covering all citations and f-tags issued, not just this specific f-tag. For the complete original report, please refer to the 'Details' section.

Summary

The facility failed to ensure that pharmacy review irregularities were properly addressed for one resident. According to facility policy, when a pharmacist makes a recommendation during the monthly drug regimen review, the physician or prescriber is required to review the recommendation, document any actions taken, and provide a rationale if no changes are made. For one resident, the pharmacist recommended considering a gradual dose reduction of Eszopiclone for insomnia and reevaluating the ongoing use of Cyclobenzaprine due to potential adverse effects. However, documentation showed only an illegible, undated initial and the word 'decline' for the Eszopiclone recommendation, with no evidence that the physician reviewed or addressed the recommendation, nor any rationale provided for declining it. Similarly, for the Cyclobenzaprine recommendation, the physician checked off that the recommendation was declined but did not provide a rationale in the resident's clinical record. Interviews with the DON confirmed the lack of proper documentation and physician response for both recommendations. These findings indicate that the facility did not follow its own policies and procedures for addressing pharmacy recommendations and documenting physician actions and rationales in the resident's health record.

An unhandled error has occurred. Reload 🗙